A randomized, controlled Phase 3 clinical trial compared VER-01, an experimental cannabis-derived drug, with opioids in 384 patients with chronic low-back pain. VER-01 was found to be superior to opioids in terms of pain reduction over 6 months of treatment. Throughout the 6 months of treatment, mean pain reduction using an 11-point numeric rating scale (NRS) was 2.50 NRS points with VER-01 versus 2.16 with opioids. These benefits were particularly pronounced in participants with severe pain, with greater pain reduction and sleep improvement compared to opioids. Furthermore, patients receiving VER-01 were four times less likely to develop constipation.
